Cornerstone Advisory’s Rocket Pharmaceuticals RCKT Stock Holding History

Cornerstone Advisory’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-18,000	Closed	-$358K	–	219
2023 Q2	$358K	Sell	18,000 -77,000	-81%	-$1.56M	0.06%	160
2023 Q1	$1.63M	Sell	95,000 -41,763	-31%	-$818K	0.29%	51
2022 Q4	$2.68M	Buy	+136,763	New	+$2.52M	0.53%	40

Other funds holding RCKT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Cornerstone Advisory's RCKT Position: Q3 2023 in Review

Cornerstone Advisory sold out of Rocket Pharmaceuticals (RCKT) in Q3 2023, closing a stake of 18,000 shares — an estimated $358K sold.

Cornerstone Advisory first reported a position in RCKT in Q4 2022 and held it in 3 quarters. The position peaked at $2.68M in Q4 2022. 175 funds tracked by Wall St. Rank hold RCKT as of Q3 2023.

Cornerstone Advisory reported no remaining Rocket Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Cornerstone Advisory sold 18,000 Rocket Pharmaceuticals shares in Q3 2023, an estimated $358K.
Cornerstone Advisory first reported a position in Rocket Pharmaceuticals in Q4 2022 and held it in 3 quarters.
Cornerstone Advisory's Rocket Pharmaceuticals position peaked at $2.68M in Q4 2022.
175 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2023.

Based on Cornerstone Advisory's 13F filing for Q3 2023, filed 14 Nov 2023.